Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,719,056
  • Shares Outstanding, K 1,635,706
  • Annual Sales, $ 22,561 M
  • Annual Income, $ 4,920 M
  • 60-Month Beta 0.74
  • Price/Sales 3.58
  • Price/Cash Flow 11.26
  • Price/Book 5.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.05
  • Number of Estimates 5
  • High Estimate 1.07
  • Low Estimate 1.03
  • Prior Year 1.01
  • Growth Rate Est. (year over year) +3.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.86 +1.83%
on 05/29/19
49.55 -7.81%
on 06/20/19
-1.13 (-2.41%)
since 05/24/19
3-Month
44.54 +2.56%
on 04/25/19
49.55 -7.81%
on 06/20/19
-2.48 (-5.15%)
since 03/22/19
52-Week
44.30 +3.12%
on 01/03/19
63.69 -28.28%
on 10/09/18
-9.46 (-17.16%)
since 06/22/18

Most Recent Stories

More News
Myasthenia Gravis Treatment Market Size, Market Trends, and Forecasts To 2026

VRX.TO : 30.80 (-3.33%)
NVS : 92.80 (+0.34%)
ABBV : 78.45 (-0.42%)
TEVA : 8.25 (-2.37%)
GSK : 40.59 (+0.79%)
BMY : 45.68 (-7.42%)
Bristol-Myers, Eldorado Resorts fall; MGM, Del Frisco's rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:

STT : 55.73 (+0.38%)
MGM : 27.92 (+0.79%)
DFRG : 7.93 (+17.83%)
FDX : 160.90 (-2.69%)
ERI : 45.77 (-10.64%)
BMY : 45.68 (-7.42%)
Why These Innovative Biotech ETFs Soaring

Strong M&A activity has sent shares of many small, innovative biotech companies surging

NVTA : 20.53 (-4.73%)
CELG : 93.47 (-5.50%)
SBIO : 35.15 (-2.31%)
ARKG : 31.85 (-2.45%)
ILMN : 357.74 (-1.06%)
ARRY : 46.23 (+0.06%)
MRK : 85.51 (+1.11%)
LLY : 115.63 (+0.12%)
PFE : 43.76 (+0.21%)
BMY : 45.68 (-7.42%)
BTEC : 33.39 (-0.91%)
Bristol-Myer Sqb Falls 7.19% on Heavy Volume: Watch For Potential Rebound

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $45.63 to a high of $46.41. Yesterday, the shares fell 7.2%, which took the trading range below the 3-day low of $47.71...

BMY : 45.68 (-7.42%)
Global Opdivo (Nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Market Review & Forecast 2017-2026 - ResearchAndMarkets.com

The "Opdivo" drug pipelines has been added to ResearchAndMarkets.com's offering.

BMY : 45.68 (-7.42%)
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG). The Company remains actively...

CELG : 93.47 (-5.50%)
CELGZ : 0.64 (unch)
BMY : 45.68 (-7.42%)
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo (nivolumab) versus sorafenib as a first-line treatment in patients...

BMY : 45.68 (-7.42%)
3 Big Biotechs Hold Growth Potential in Second Half of 2019

We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

CELG : 93.47 (-5.50%)
ARRY : 46.23 (+0.06%)
VRTX : 181.02 (-1.60%)
GILD : 68.84 (-0.78%)
BMY : 45.68 (-7.42%)
ALXN : 126.98 (-4.09%)
Bristol-Myer Sqb (BMY) Approaches New Upside Target of $46.64

Shares of Bristol-Myer Sqb (NYSE:BMY) have bullishly opened above the pivot of $46.27 today and have reached the first resistance level of $46.40. Analysts will be watching for a cross of the next upside...

BMY : 45.68 (-7.42%)
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

AZN : 41.49 (+0.31%)
MRK : 85.51 (+1.11%)
JNJ : 143.06 (+0.68%)
LLY : 115.63 (+0.12%)
RHHBY : 35.3850 (-0.60%)
SNY : 43.84 (-0.70%)
BMY : 45.68 (-7.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 48.10
1st Resistance Point 46.89
Last Price 45.68
1st Support Level 45.02
2nd Support Level 44.36

See More

52-Week High 63.69
Fibonacci 61.8% 56.28
Fibonacci 50% 53.99
Fibonacci 38.2% 51.71
Last Price 45.68
52-Week Low 44.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar